118 related articles for article (PubMed ID: 19365781)
1. Preparation and characterization of marine sponge collagen nanoparticles and employment for the transdermal delivery of 17beta-estradiol-hemihydrate.
Nicklas M; Schatton W; Heinemann S; Hanke T; Kreuter J
Drug Dev Ind Pharm; 2009 Sep; 35(9):1035-42. PubMed ID: 19365781
[TBL] [Abstract][Full Text] [Related]
2. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol.
Scott RT; Ross B; Anderson C; Archer DF
Obstet Gynecol; 1991 May; 77(5):758-64. PubMed ID: 2014092
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle delivery for transdermal HRT.
Valenzuela P; Simon JA
Nanomedicine; 2012 Sep; 8 Suppl 1():S83-9. PubMed ID: 22640909
[TBL] [Abstract][Full Text] [Related]
5. Solid lipid nanoparticles (SLN) as carriers for the topical delivery of econazole nitrate: in-vitro characterization, ex-vivo and in-vivo studies.
Sanna V; Gavini E; Cossu M; Rassu G; Giunchedi P
J Pharm Pharmacol; 2007 Aug; 59(8):1057-64. PubMed ID: 17725847
[TBL] [Abstract][Full Text] [Related]
6. [Bioavailability of 17 beta-estradiol after transdermal administration--dependence on the patch system].
Schmolling J; Kusche J; van der Ven H; Schander K
Zentralbl Gynakol; 1998; 120(3):121-5. PubMed ID: 9556902
[TBL] [Abstract][Full Text] [Related]
7. Three-year follow-up of the use of transdermal 17beta-estradiol matrix patches for the prevention of bone loss in early postmenopausal women.
Delmas PD; Pornel B; Felsenberg D; Stakkestad JA; Radowicki S; Garnero P; Hardy P; Dain MP; Petitier B;
Am J Obstet Gynecol; 2001 Jan; 184(2):32-40. PubMed ID: 11174476
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of weekly transdermal estradiol controlled delivery system in postmenopausal Chinese.
Chen GS; Zhang MY; Wang Q; Ye JC
Zhongguo Yao Li Xue Bao; 1996 Sep; 17(5):407-10. PubMed ID: 9863160
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of estradiol and of estrone during application of a new 7-day estradiol transdermal patch with active matrix.
Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
Arzneimittelforschung; 1998 Mar; 48(3):275-85. PubMed ID: 9553686
[TBL] [Abstract][Full Text] [Related]
10. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting.
Wang X; Chi N; Tang X
Eur J Pharm Biopharm; 2008 Nov; 70(3):735-40. PubMed ID: 18684400
[TBL] [Abstract][Full Text] [Related]
11. [Kinetics of a new patch for transdermal administration of 17 beta-estradiol].
Rohr UD; Nauert C; Ehrly AM
Zentralbl Gynakol; 1995; 117(10):531-9. PubMed ID: 7491836
[TBL] [Abstract][Full Text] [Related]
12. Enhanced transdermal permeability of estradiol using combination of PLGA nanoparticles system and iontophoresis.
Tomoda K; Watanabe A; Suzuki K; Inagi T; Terada H; Makino K
Colloids Surf B Biointerfaces; 2012 Sep; 97():84-9. PubMed ID: 22609586
[TBL] [Abstract][Full Text] [Related]
13. Chemical and structural investigation of lipid nanoparticles: drug-lipid interaction and molecular distribution.
Anantachaisilp S; Smith SM; Treetong A; Pratontep S; Puttipipatkhachorn S; Ruktanonchai UR
Nanotechnology; 2010 Mar; 21(12):125102. PubMed ID: 20182010
[TBL] [Abstract][Full Text] [Related]
14. Steady-state pharmacokinetics following application of a novel transdermal estradiol spray in healthy postmenopausal women.
Morton TL; Gattermeir DJ; Petersen CA; Day WW; Schumacher RJ
J Clin Pharmacol; 2009 Sep; 49(9):1037-46. PubMed ID: 19628730
[TBL] [Abstract][Full Text] [Related]
15. [Transdermal and oral hormone substitution with estrogens: a comparison].
Schindler AE
Zentralbl Gynakol; 1995; 117(10):504-7. PubMed ID: 7491831
[TBL] [Abstract][Full Text] [Related]
16. [Plasma levels of total cholesterol, LDL-cholesterol, and HDL-cholesterol in postmenopausal women during 12 months' oral administration of dydrogesterone or medroxyprogesterone combined with continuous transdermal supplementation of 17beta-estradiol].
Milewicz T; Kostecka A; Rogatko I; Sztefko K; Kwiatkowska-Panek E; Radowick S; Krzysiek J
Przegl Lek; 2007; 64(2):65-9. PubMed ID: 17892034
[TBL] [Abstract][Full Text] [Related]
17. [Effect of particle size on oral absorption of silymarin-loaded solid lipid nanoparticles].
He J; Hou SX; Feng JF; Cai BQ
Zhongguo Zhong Yao Za Zhi; 2005 Nov; 30(21):1651-3. PubMed ID: 16400939
[TBL] [Abstract][Full Text] [Related]
18. Effects of transdermal and oral estrogen replacement on lipids and glucose metabolism in postmenopausal women with type 2 diabetes mellitus.
Araújo DA; Farias ML; Andrade AT
Climacteric; 2002 Sep; 5(3):286-92. PubMed ID: 12419087
[TBL] [Abstract][Full Text] [Related]
19. Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice.
Henzl MR; Loomba PK
J Reprod Med; 2003 Jul; 48(7):525-40. PubMed ID: 12953327
[TBL] [Abstract][Full Text] [Related]
20. The effects of skin-to-skin contact, application site washing, and sunscreen use on the pharmacokinetics of estradiol from a metered-dose transdermal spray.
Schumacher RJ; Gattermeir DJ; Peterson CA; Wisdom C; Day WW
Menopause; 2009; 16(1):177-83. PubMed ID: 18779758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
